ストックスクリーナーアプリを入手
36.01
0.33%
-0.12
アフターアワーズ：
35.99
-0.02
-0.06%
前日終値:
$36.13
開ける：
$36.625
24時間の取引高:
1.48M
Relative Volume:
1.92
時価総額：
$2.09B
収益：
$32.87M
当期純損益:
$674.31M
株価収益率:
3.1699
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-4.51%
1か月 パフォーマンス:
-0.55%
6か月 パフォーマンス:
+6.07%
1年 パフォーマンス:
-18.23%
1日の値動き範囲:
$35.91
$37.91
1週間の範囲:
$32.70
$41.10
52週間の値動き範囲:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
36.01 | 2.10B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Gains Report & Weekly Setup with High ROI Potential - Newser
Statistical indicators supporting Agios Pharmaceuticals Inc.’s strengthJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - Newser
Is Agios Pharmaceuticals Inc. backed by strong institutional buyingQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - خودرو بانک
What is Agios Pharmaceuticals Inc.’s market positionJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - خودرو بانک
Liver Injury REMS Delays US FDA Approval Of Agios’s Pyrukynd In Thalassemia - insights.citeline.com
Will Agios Pharmaceuticals Inc. outperform tech stocksTrend Reversal & Daily Chart Pattern Signals - خودرو بانک
Agios drops as FDA delays review of thalassemia drug - MSN
Can Agios Pharmaceuticals Inc. withstand a market correctionJuly 2025 Fed Impact & AI Enhanced Trading Signals - خودرو بانک
Agios Pharma stock faces FDA delay as PDUFA date extended for Pyrukynd - Investing.com Canada
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia - Yahoo Finance
Backtesting results for Agios Pharmaceuticals Inc. trading strategiesTrade Volume Report & High Conviction Buy Zone Picks - Newser
FDA extends review period for Agios’ thalassemia drug By Investing.com - Investing.com Canada
Detecting support and resistance levels for Agios Pharmaceuticals Inc.Recession Risk & Weekly High Return Forecasts - Newser
Combining machine learning predictions for Agios Pharmaceuticals Inc.Market Trend Summary & Risk Managed Trade Strategies - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockWeekly Profit Report & Weekly Consistent Profit Watchlists - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Sentiment Summary & Consistent Growth Equity Picks - Newser
Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia - insights.citeline.com
Agios Pharma stock falls as BofA lowers price target on PDUFA delay - Investing.com Canada
Agios Pharma stock faces FDA delay as PDUFA date extended for thalassemia drug - Investing.com Canada
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More - Stocktwits
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
Agios Pharmaceuticals shares fall 13.52% intraday after FDA delays PDUFA target date for PYRUKYND. - AInvest
FDA delays decision on Agios drug in thalassemia over liver safety - Endpoints News
Why Did Agios Plunge 26.94%? FDA Delays PYRUKYND Review - AInvest
Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest
Agios stock drops as FDA delays Pyrukynd review (AGIO:NASDAQ) - Seeking Alpha
FDA extends review period for Agios’ thalassemia drug - Investing.com
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - The Manila Times
FDA Extends Review of First Oral Treatment for Thalassemia: Agios' PYRUKYND Decision Set for December - Stock Titan
Is Agios Pharmaceuticals Inc. stock ready for a breakout2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is Agios Pharmaceuticals Inc. trending in predictive chart models2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
Price momentum metrics for Agios Pharmaceuticals Inc. explainedIPO Watch & Free Growth Oriented Trading Recommendations - Newser
Should you hold or exit Agios Pharmaceuticals Inc. nowJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Is Agios Pharmaceuticals Inc. still worth holding after the dip2025 Market WrapUp & AI Based Buy and Sell Signals - Newser
Full technical analysis of Agios Pharmaceuticals Inc. stockTrade Volume Summary & Verified Swing Trading Watchlist - Newser
How to forecast Agios Pharmaceuticals Inc. trends using time seriesM&A Rumor & Fast Entry Momentum Alerts - Newser
Is Agios Pharmaceuticals Inc. undervalued by DCF analysisMarket Sentiment Review & Reliable Momentum Entry Alerts - خودرو بانک
Should you wait for a breakout in Agios Pharmaceuticals Inc.2025 Retail Activity & Fast Exit Strategy with Risk Control - Newser
Price action breakdown for Agios Pharmaceuticals Inc.Portfolio Value Summary & High Yield Stock Recommendations - Newser
Long term hold vs stop loss in Agios Pharmaceuticals Inc.Treasury Yields & Daily Chart Pattern Signal Reports - Newser
What MACD signals say about Agios Pharmaceuticals Inc.Weekly Stock Recap & Technical Buy Zone Confirmations - Newser
Developing predictive dashboards with Agios Pharmaceuticals Inc. dataIndex Update & Fast Momentum Entry Tips - Newser
Historical volatility pattern of Agios Pharmaceuticals Inc. visualizedEarnings Growth Summary & Daily Technical Forecast Reports - Newser
Chart Patterns Forming a Bullish Setup in Agios Pharmaceuticals Inc.Sell Signal & Free High Return Stock Watch Alerts - beatles.ru
Can trapped investors hope for a rebound in Agios Pharmaceuticals Inc.Trade Volume Report & Weekly Stock Breakout Alerts - Newser
How to track smart money flows in Agios Pharmaceuticals Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Can Agios Pharmaceuticals Inc. deliver consistent EPS growthWeekly Stock Recap & Weekly High Return Stock Opportunities - خودرو بانک
Is Agios Pharmaceuticals Inc. a turnaround storyJuly 2025 Summary & High Accuracy Investment Entry Signals - خودرو بانک
Commit To Buy Agios Pharmaceuticals At $30, Earn 34.9% Annualized Using Options - Nasdaq
Using AI based signals to follow Agios Pharmaceuticals Inc.Quarterly Trade Review & High Accuracy Trade Alerts - Newser
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):